JP7340459B2 - 新規ｐｓｍａ結合剤及びその使用 - Google Patents

新規ｐｓｍａ結合剤及びその使用 Download PDF

Info

Publication number
JP7340459B2
JP7340459B2 JP2019562312A JP2019562312A JP7340459B2 JP 7340459 B2 JP7340459 B2 JP 7340459B2 JP 2019562312 A JP2019562312 A JP 2019562312A JP 2019562312 A JP2019562312 A JP 2019562312A JP 7340459 B2 JP7340459 B2 JP 7340459B2
Authority
JP
Japan
Prior art keywords
psma
pharmaceutically acceptable
solvate
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019562312A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520902A (ja
JP2020520902A5 (enExample
Inventor
マルティナ・ベネソヴァ
クリスティーナ・ミュラー
クリストフ・アンブリット
ロジャー・シブリ
コンスタンティン・ツェルノゼコフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scherrer Paul Institut
Original Assignee
Scherrer Paul Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/000717 external-priority patent/WO2018233798A1/en
Application filed by Scherrer Paul Institut filed Critical Scherrer Paul Institut
Publication of JP2020520902A publication Critical patent/JP2020520902A/ja
Publication of JP2020520902A5 publication Critical patent/JP2020520902A5/ja
Application granted granted Critical
Publication of JP7340459B2 publication Critical patent/JP7340459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5229—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image
    • A61B6/5235—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image combining images from the same or different ionising radiation imaging techniques, e.g. PET and CT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019562312A 2017-05-24 2018-05-24 新規ｐｓｍａ結合剤及びその使用 Active JP7340459B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17000891.6 2017-05-24
EP17000891 2017-05-24
PCT/EP2017/000717 WO2018233798A1 (en) 2017-06-20 2017-06-20 Novel psma-binding agents and uses thereof
EPPCT/EP2017/000717 2017-06-20
PCT/EP2018/063734 WO2018215627A1 (en) 2017-05-24 2018-05-24 Novel psma-binding agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2020520902A JP2020520902A (ja) 2020-07-16
JP2020520902A5 JP2020520902A5 (enExample) 2021-07-26
JP7340459B2 true JP7340459B2 (ja) 2023-09-07

Family

ID=62200468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019562312A Active JP7340459B2 (ja) 2017-05-24 2018-05-24 新規ｐｓｍａ結合剤及びその使用

Country Status (9)

Country Link
US (1) US11629201B2 (enExample)
EP (1) EP3630204A1 (enExample)
JP (1) JP7340459B2 (enExample)
KR (1) KR102843240B1 (enExample)
CN (1) CN110740757B (enExample)
AU (1) AU2018274184B2 (enExample)
CA (1) CA3060143A1 (enExample)
WO (1) WO2018215627A1 (enExample)
ZA (1) ZA201906832B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
US12228480B2 (en) * 2018-11-30 2025-02-18 Revvity Health Sciences, Inc. Biological sample preparation using electric fields
AU2020208492A1 (en) * 2019-01-17 2021-08-12 Case Western Reserve University Peptide PET/SPECT probes specific to oncoproteins in tumor extracellular matrix
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
EP3976025A4 (en) * 2019-05-24 2023-05-17 Clarity Pharmaceuticals Limited PSMA IMAGING AGENT FORMULATIONS
AU2020296488A1 (en) 2019-06-21 2022-01-20 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
TWI803688B (zh) * 2019-08-26 2023-06-01 行政院原子能委員會核能研究所 一種psma靶向放射診療藥物備製方法
KR102269315B1 (ko) * 2019-10-24 2021-06-24 서울대학교산학협력단 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
CA3210294A1 (en) * 2021-03-04 2022-09-09 Yoshifumi Maya Compound and radioactive labeling compound
CA3223227A1 (en) * 2021-05-21 2022-11-24 NorthStar Medical Technologies, LLC Urokinase plasminogen activator receptor-targeted radiopharmaceutical
WO2023030509A1 (zh) * 2021-09-03 2023-03-09 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
TW202321204A (zh) * 2021-11-10 2023-06-01 大陸商蘇州瑞核醫藥科技有限公司 靶向前列腺特異性膜抗原的配體化合物及其螯合物與用於前列腺癌診斷和治療的應用
EP4436979A1 (en) * 2021-11-26 2024-10-02 Full-Life Technologies HK Limited Cleavable radioligands for targeting cell surface receptors and uses thereof
AU2023226956A1 (en) * 2022-03-04 2024-09-12 Provincial Health Services Authority Radiolabeled compounds targetng the prostate-specific membrane antigen
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
KR20250057886A (ko) * 2022-09-07 2025-04-29 쓰리비 파마슈티컬스 게엠베하 전립선 특이적 막 항원 (psma) 리간드 및 그의 용도
WO2024051794A1 (zh) * 2022-09-09 2024-03-14 同宜医药（苏州）有限公司 放射性核素偶联药物及其药物组合物和应用
CN120282804A (zh) * 2022-09-23 2025-07-08 核素迪姆股份公司 高纯度铜放射性药物组合物及其诊断和治疗用途
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
KR20250148672A (ko) * 2023-02-16 2025-10-14 노로이 바이오사이언스 씨오., 엘티디. Psma 표적 방사성 약물 및 그 합성과 응용
WO2024245421A1 (en) * 2023-05-31 2024-12-05 Full-Life Technologies Hk Limited Radioligands for targeting cell surface receptors and uses thereof
AU2024282453A1 (en) * 2023-05-31 2025-12-04 Full-Life Technologies Hk Limited Conjugates and uses thereof
CN120265331A (zh) 2023-07-31 2025-07-04 美国锔责任有限公司 [177Lu]镥-PSMA I&T组合物及其剂量测定、试剂盒、制备方法和使用方法
WO2025088147A1 (en) * 2023-10-27 2025-05-01 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis
WO2025218879A1 (en) 2024-04-15 2025-10-23 Itm Technologies Munich Se Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019534846A (ja) 2016-08-10 2019-12-05 キャンサー ターゲテッド テクノロジー エルエルシー キレート化されたｐｓｍａ阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US9687572B2 (en) * 2010-12-06 2017-06-27 Molecular Insight Pharmaceuticals, Inc. PSMA-targeted dendrimers
ES2732060T3 (es) 2011-08-05 2019-11-20 Molecular Insight Pharm Inc Inhibidores radiomarcados del antígeno de membrana específico de la próstata
HUE068833T2 (hu) 2011-08-17 2025-01-28 Merck & Cie Kmg Albumint megkötõ egységek folát konjugátjai
ES2743433T3 (es) 2013-03-15 2020-02-19 Cancer Targeted Tech Llc Agentes para imágenes de pet dirigidos a psma marcados con 18F
AU2014336638C1 (en) * 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019534846A (ja) 2016-08-10 2019-12-05 キャンサー ターゲテッド テクノロジー エルエルシー キレート化されたｐｓｍａ阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The Journal of Nuclear Medicine，2017年09月，vol.58, no.9，p.1442-1449
Theranostics，2017年，vol.7, issue 7，p.1928-1939

Also Published As

Publication number Publication date
KR20200009091A (ko) 2020-01-29
CA3060143A1 (en) 2018-11-29
RU2019141963A (ru) 2021-06-24
AU2018274184A1 (en) 2019-11-07
CN110740757B (zh) 2023-04-04
JP2020520902A (ja) 2020-07-16
ZA201906832B (en) 2024-02-28
RU2019141963A3 (enExample) 2021-09-22
CN110740757A (zh) 2020-01-31
AU2018274184B2 (en) 2024-06-13
US20210009715A1 (en) 2021-01-14
KR102843240B1 (ko) 2025-08-05
US11629201B2 (en) 2023-04-18
WO2018215627A1 (en) 2018-11-29
EP3630204A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
JP7340459B2 (ja) 新規ｐｓｍａ結合剤及びその使用
JP7729441B2 (ja) 腫瘍抗原標的化剤、医薬組成物、癌診断薬又は癌治療薬、ｉｎ ｖｉｔｒｏ法、及びその化合物
AU2024200440B2 (en) Dual mode radiotracer and -therapeutics
Benešová et al. Albumin-binding PSMA ligands: optimization of the tissue distribution profile
CA2924360C (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP7549585B2 (ja) がん診断用画像化剤
WO2022186311A1 (ja) 化合物及び放射性標識化合物
CN117120099A (zh) 双模式放射性示踪剂和疗法
WO2018233798A1 (en) Novel psma-binding agents and uses thereof
RU2831681C2 (ru) Новые связывающие опухолевый антиген агенты и их применение
RU2787105C2 (ru) Новые пса-связывающие агенты и их применение
HK40054611A (en) Novel tumor antigen binding agents and uses thereof
WO2025171887A1 (en) Radiolabeled complexes and pharmaceutical compositions including the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210521

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230828

R150 Certificate of patent or registration of utility model

Ref document number: 7340459

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150